Emergency department-initiated buprenorphine vs brief intervention for opioid use disorder: a systematic review and meta-analysis of clinical trials
Abstract
Introduction: Emergency departments (EDs) are critical points of contact for individuals at high risk, as opioid use disorder (OUD) remains a major public health crisis. While Screening, Brief Intervention, and Referral to Treatment (SBIRT) andother brief intervention (BI) models have been promoted as pragmatic approaches in acute care, their efficacy for OUD is uncertain. In contrast, ED-initiated buprenorphine (BUP) has shown promise for improving outcomes, but comparative trial data require synthesis.
Methods: Following PRISMA 2020 guidelines, we reviewed randomized and nonrandomized clinical trials comparing ED-initiated BUP with BI, referral, or usual care. Primary outcomes were treatment engagement and retention; secondary outcomes included opioid use, overdose risk behaviors, and healthcare utilization. Searches were conducted in PubMed, Scopus, Google Scholar, Web of Science, and trial registries through January 29, 2025. Risk of bias was assessed using ROB-2, and data were pooled via random-effects models.
Findings: Nine trials (n = 1,172), primarily from North America, met inclusion criteria. Compared with BI (52%), BUP initiation yielded higher adherence (61%) and lower opioid use prevalence (17% vs. 28%). Multiple RCTs consistently favored BUP for short-term engagement, whereas BI showed minimal effects on treatment utilization, overdose risk, or substance use outcomes. Considerable heterogeneity (I2 ≈ 99%) and potential publication bias were observed.…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,172 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.